CA
NZ
UK
AU
IND
US
• No fresh company-specific catalyst was identified, suggesting bargain buying and sector momentum are supporting the move.
• Existing ENDRA shareholders are expected to own approximately 3% of the combined Noble Africa company.
• Positive early-stage combination data in MTAP-deleted cancers continue to support the company’s oncology valuation.
• An earlier eGFR analysis could bring a major atacicept regulatory milestone into the third quarter of 2026.
• The move follows a 5.95% decline in the previous session, suggesting bargain buying and a technical rebound.
• Nuvectis Pharma is down 2.08% intraday at $23.97 in orderly selling without a panicked character, consistent with routine profit-taking after an active recent period.
• Palvella Therapeutics is up 2.80% intraday at $133.47, with thin trading and the gain reflecting passive sector-level accumulation rather than directional news-driven buying.
• Personalis is up 9.33% intraday at $12.42 with above-average volume, with the bulk of the gain occurring at the open and then holding, consistent with short-covering followed by lighter sustained buying.
• Quanterix is up 2.12% intraday at $3.86 with above-average volume, suggesting the Bio-Techne M&A catalyst is generating genuine interest rather than passive drift.
• Repligen is up 5.38% intraday at $145.84, holding near session highs on above-average volume, a technically constructive sign of sustained institutional buying.
Please wait processing your request...